Computer-aided Vaccine and Drug Discovery GPS Raghava
... NetChop: For Proteasome and immunoproteasome. Based on MHC class I ligand data using ANN Recently, these three methods has been evaluated on independent dataset. The results showed that NetChop (MCC=0.32) is better then rest of methods. (Saxova et al., 2003). Low accuracy of all methods motivated us ...
... NetChop: For Proteasome and immunoproteasome. Based on MHC class I ligand data using ANN Recently, these three methods has been evaluated on independent dataset. The results showed that NetChop (MCC=0.32) is better then rest of methods. (Saxova et al., 2003). Low accuracy of all methods motivated us ...
Macrolids
... individuals with infections caused by staphylococci (assuming that the isolate is susceptible), streptococci, or pneumococci. Emergence of erythromycin resistance in strains of group A streptococci and pneumococci (penicillin-resistant pneumococci in particular) has made macrolides less attractive a ...
... individuals with infections caused by staphylococci (assuming that the isolate is susceptible), streptococci, or pneumococci. Emergence of erythromycin resistance in strains of group A streptococci and pneumococci (penicillin-resistant pneumococci in particular) has made macrolides less attractive a ...
Kinetic analysis of cooperativity of phosphorylated L
... and consist of similar subunits [2]. Three of these isoenzymes, M2, L, and R, show allosteric properties for binding PEP under physiological conditions [3, 4]. This means that the binding of a substrate molecule at one site of multimeric enzyme may affect ligand binding at other sites. Such communi ...
... and consist of similar subunits [2]. Three of these isoenzymes, M2, L, and R, show allosteric properties for binding PEP under physiological conditions [3, 4]. This means that the binding of a substrate molecule at one site of multimeric enzyme may affect ligand binding at other sites. Such communi ...
Magnetic nanoparticles for drug delivery
... characteristics of NPs are different from those of bulk materials of ...
... characteristics of NPs are different from those of bulk materials of ...
role of phenobarbitone as an antiepileptic drug in 21st century
... in cats by Merritt and Putnam, a second effective anti-convulsant, namely, phenytoin was introduced. Since then a gamut of anti-epileptic drugs have been introduced following the systematic screening of many thousands of compounds in animal models of epilepsy.1 Although the therapeutic options in ph ...
... in cats by Merritt and Putnam, a second effective anti-convulsant, namely, phenytoin was introduced. Since then a gamut of anti-epileptic drugs have been introduced following the systematic screening of many thousands of compounds in animal models of epilepsy.1 Although the therapeutic options in ph ...
Ocular Drug Delivery
... via either the topical or systemic route. Topical application remains the most preferred route due to ease of administration, low cost, and patient compliance. It is generally useful in the treatment of anterior segment disorders [4]. Drug delivery to the posterior segment still is a major challenge ...
... via either the topical or systemic route. Topical application remains the most preferred route due to ease of administration, low cost, and patient compliance. It is generally useful in the treatment of anterior segment disorders [4]. Drug delivery to the posterior segment still is a major challenge ...
Carbinoxamine Maleate
... Neonates have an increased susceptibility to anticholinergic side effects, such as CNS excitation, which may lead to convulsions. Carbinoxamine maleate may diminish mental alertness in children. In the young child, particularly, they may produce excitation. Geriatric Use: Carbinoxamine maleate is mo ...
... Neonates have an increased susceptibility to anticholinergic side effects, such as CNS excitation, which may lead to convulsions. Carbinoxamine maleate may diminish mental alertness in children. In the young child, particularly, they may produce excitation. Geriatric Use: Carbinoxamine maleate is mo ...
Senior Honors Thesis - Deep Blue
... A second key advantage of an acrylamide matrix is its high engineerability. Due to the synthetic nature of these particles, their size can be tuned within a very broad range, from below the tens of nanometers in diameter upward. In addition to size, the charge of the nanoparticle can also be control ...
... A second key advantage of an acrylamide matrix is its high engineerability. Due to the synthetic nature of these particles, their size can be tuned within a very broad range, from below the tens of nanometers in diameter upward. In addition to size, the charge of the nanoparticle can also be control ...
Drug action
... Yvette, a new patient, has been diagnosed by the physician as hypertensive. The physician has prescribed two new medications for her to take. Yvette is also taking several other medications for osteoarthritis and allergies; these were prescribed by another physician, but she cannot remember all of t ...
... Yvette, a new patient, has been diagnosed by the physician as hypertensive. The physician has prescribed two new medications for her to take. Yvette is also taking several other medications for osteoarthritis and allergies; these were prescribed by another physician, but she cannot remember all of t ...
ANALYTICAL METHODS FORTAXANES QUANTIFICATION IN DILUTED FORMULATIONS AND
... adjustments). It could also represent an increased burden for the patient [59]. ...
... adjustments). It could also represent an increased burden for the patient [59]. ...
enclosure-ii
... convenience, good patient compliance and low medicine production costs. In order for a drug to be absorbed into the systemic circulation following oral administration, the drug must be dissolved in the gastric fluids. For hydrophobic drugs, the dissolution process acts as the rate-controlling step a ...
... convenience, good patient compliance and low medicine production costs. In order for a drug to be absorbed into the systemic circulation following oral administration, the drug must be dissolved in the gastric fluids. For hydrophobic drugs, the dissolution process acts as the rate-controlling step a ...
Halogen Bond: Its Role beyond Drug–Target
... more halogenated drugs (34%) are in clinic trials or at the stage of pre- and registered than that in the drugs launched (26%), implying that halogenations have been much appreciated nowadays. It is well-known that natural products contain little halogens in their structures. Therefore, halogenation ...
... more halogenated drugs (34%) are in clinic trials or at the stage of pre- and registered than that in the drugs launched (26%), implying that halogenations have been much appreciated nowadays. It is well-known that natural products contain little halogens in their structures. Therefore, halogenation ...
Novel approaches for the treatment of psychostimulant/opioid abuse
... The ideal novel treatment for drug addiction would be effective against all classes of drugs of abuse (opioids and psychostimulants, but also alcohol and nicotine). By considering the basic pharmacology of these drugs of abuse, at first glance, this would seem unlikely. The rewarding properties of a ...
... The ideal novel treatment for drug addiction would be effective against all classes of drugs of abuse (opioids and psychostimulants, but also alcohol and nicotine). By considering the basic pharmacology of these drugs of abuse, at first glance, this would seem unlikely. The rewarding properties of a ...
cdph/oa/adap - Magellan Rx
... Management will request additional information (client and drug specific) before considering the authorization. Please call 1-800-424-5906 or check website for diagnosis or specific PA form at https://cdph.magellanrx.com. ...
... Management will request additional information (client and drug specific) before considering the authorization. Please call 1-800-424-5906 or check website for diagnosis or specific PA form at https://cdph.magellanrx.com. ...
OVERVIEW OF THE ANTIDIABETIC AGENTS
... symptoms of diabetes in the ~80% of patients having NIDDM. Since insulin resistance and impaired insulin secretion are key factors in the pathogenesis of NIDDM, treatment should be directed toward restoring metabolic normality by improving insulin secretion and reducing insulin resistance. These goa ...
... symptoms of diabetes in the ~80% of patients having NIDDM. Since insulin resistance and impaired insulin secretion are key factors in the pathogenesis of NIDDM, treatment should be directed toward restoring metabolic normality by improving insulin secretion and reducing insulin resistance. These goa ...
PATTON BOGGS, L.L. P. 1660
... Page 8 The term “controlled substance” means a drug or other substance, or immediate precursor, included in schedule I, II, III, IV, or V of part B of this subchapter. These five schedules of controlled substances are a part of 21 U.s.c. S812. In the United Statesr there are three criteria which mus ...
... Page 8 The term “controlled substance” means a drug or other substance, or immediate precursor, included in schedule I, II, III, IV, or V of part B of this subchapter. These five schedules of controlled substances are a part of 21 U.s.c. S812. In the United Statesr there are three criteria which mus ...
Drug Review - Shodhganga
... to the application of heat or any vesicant alkaline solution as well as in bite of wild beasts and birds etc. and act beneficially in baths, unguents and lubrication Pharmacological Action : Sneha – because of qualities like Ushma, Tikshna, Vyavayi and Sukshma, reaches up to the microchannel levels, ...
... to the application of heat or any vesicant alkaline solution as well as in bite of wild beasts and birds etc. and act beneficially in baths, unguents and lubrication Pharmacological Action : Sneha – because of qualities like Ushma, Tikshna, Vyavayi and Sukshma, reaches up to the microchannel levels, ...
The Effect of Changes in Co-payment and Premium Policies
... Policy makers are well-aware of this evidence, but given the fiscal realities facing provincial drug programs, they see cost-sharing policies, including co-payments, as vital to program sustainability. In the absence of effective measures to control the growth in prescription drug use and overall co ...
... Policy makers are well-aware of this evidence, but given the fiscal realities facing provincial drug programs, they see cost-sharing policies, including co-payments, as vital to program sustainability. In the absence of effective measures to control the growth in prescription drug use and overall co ...
13. Major R&D Pipeline In-House R&D Pipeline List New Approval
... Description: Increases levels of the neurotransmitter acetylcholine in the brain by inhibiting its breakdown by the enzyme acetylcholinesterase, thereby slowing the overall progression of symptoms associated with Alzheimer’s disease (AD). Currently approved in more than 90 countries around the world ...
... Description: Increases levels of the neurotransmitter acetylcholine in the brain by inhibiting its breakdown by the enzyme acetylcholinesterase, thereby slowing the overall progression of symptoms associated with Alzheimer’s disease (AD). Currently approved in more than 90 countries around the world ...
the WHO Herbal Dictionary
... To enter a drug in the dictionary you need to provide us with some basic facts about the requested drug. If you request a large number of entries you might prefer to enter the request in an electronic Excel format. Contact the UMC for more information. Please notice that the entry of herbal product ...
... To enter a drug in the dictionary you need to provide us with some basic facts about the requested drug. If you request a large number of entries you might prefer to enter the request in an electronic Excel format. Contact the UMC for more information. Please notice that the entry of herbal product ...
< . 4- c
... Under 21 U.S. C. 350b(a), the manufacturer or distributor of a dietary supplement that contains a new dietary ingredient that has not been present in the food supply as an article used for food in a form in which the food has not been chemically altered must submit to FDA, at least 75 days before th ...
... Under 21 U.S. C. 350b(a), the manufacturer or distributor of a dietary supplement that contains a new dietary ingredient that has not been present in the food supply as an article used for food in a form in which the food has not been chemically altered must submit to FDA, at least 75 days before th ...
Volume 30 • Number 6 • 2013 - Controlled Release Society
... and Südhof elucidated signals to instruct vesicles to release the cargo when required. Using a phrase that could have come from CRS, one press release reported: “timing and location are everything.” Since most of their work was published in the 1970s, 1980s, and 1990s, this material is now standard ...
... and Südhof elucidated signals to instruct vesicles to release the cargo when required. Using a phrase that could have come from CRS, one press release reported: “timing and location are everything.” Since most of their work was published in the 1970s, 1980s, and 1990s, this material is now standard ...
Drug design
Drug design, sometimes referred to as rational drug design or simply rational design, is the inventive process of finding new medications based on the knowledge of a biological target. The drug is most commonly an organic small molecule that activates or inhibits the function of a biomolecule such as a protein, which in turn results in a therapeutic benefit to the patient. In the most basic sense, drug design involves the design of molecules that are complementary in shape and charge to the biomolecular target with which they interact and therefore will bind to it. Drug design frequently but not necessarily relies on computer modeling techniques. This type of modeling is often referred to as computer-aided drug design. Finally, drug design that relies on the knowledge of the three-dimensional structure of the biomolecular target is known as structure-based drug design. In addition to small molecules, biopharmaceuticals and especially therapeutic antibodies are an increasingly important class of drugs and computational methods for improving the affinity, selectivity, and stability of these protein-based therapeutics have also been developed.The phrase ""drug design"" is to some extent a misnomer. A more accurate term is ligand design (i.e., design of a molecule that will bind tightly to its target). Although design techniques for prediction of binding affinity are reasonably successful, there are many other properties, such as bioavailability, metabolic half-life, side effects, etc., that first must be optimized before a ligand can become a safe and efficacious drug. These other characteristics are often difficult to predict with rational design techniques. Nevertheless, due to high attrition rates, especially during clinical phases of drug development, more attention is being focused early in the drug design process on selecting candidate drugs whose physicochemical properties are predicted to result in fewer complications during development and hence more likely to lead to an approved, marketed drug. Furthermore, in vitro experiments complemented with computation methods are increasingly used in early drug discovery to select compounds with more favorable ADME (absorption, distribution, metabolism, and excretion) and toxicological profiles.